Table 2.
Heart rates before, during, and after scenario completion, per study group (N=150).
|
|
Heart rate (bpma) | |||
|
|
Mobile app (n=73), mean (SD) | Conventional method (n=76), mean (SD) | Difference (95% CI)b | P value |
| Baseline | 79.3 (14.4) | 78.5 (12.7) | 1.0 (−3.3 to 5.3) | .64 |
| First drug, HRcpeak | 123.1 (9.2) | 124.1 (12.2) | −1.1 (−4.7 to 2.4) | .53 |
| Second drug, HRpeak | 121.1 (10.9) | 119.9 (13.3) | 1.0 (−2.8 to 4.8) | .61 |
| Third drug, HRpeak | 120.4 (11.4) | 117.9 (13.3) | 2.4 (−1.4 to 6.2) | .22 |
| Fourth drug, HRpeak | 114.1 (13.5) | 110.5 (13.7) | 3.4 (−0.9 to 7.6) | .12 |
| Recovery | 79.3 (15.0) | 76.8 (13.7) | 1.9 (−2.3 to 6.1) | .37 |
| Maximal HRpeakd | 126.1 (10.3) | 126.0 (12.1) | −0.1 (−3.8 to 3.5) | .95 |
abpm: beats per minute.
bLinear regression models adjusted for center and baseline heart rate using linear regression models (except for baseline heart rate adjusted for center only). A negative difference means that the average value is lower with than without PedAMINES.
cHR: heart rate.
dHighest value of HRpeak among the 4 drugs.